PETX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PETX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aratana Therapeutics's share price for the quarter that ended in Mar. 2019 was $3.6. Aratana Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2019 was 48.35 Mil. Therefore, Aratana Therapeutics's market cap for the quarter that ended in Mar. 2019 was $174.05 Mil.
Aratana Therapeutics's quarterly market cap increased from Sep. 2018 ($280.21 Mil) to Dec. 2018 ($294.54 Mil) but then declined from Dec. 2018 ($294.54 Mil) to Mar. 2019 ($174.05 Mil).
Aratana Therapeutics's annual market cap declined from Dec. 2016 ($262.84 Mil) to Dec. 2017 ($223.72 Mil) but then increased from Dec. 2017 ($223.72 Mil) to Dec. 2018 ($294.54 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aratana Therapeutics's Enterprise Value for Today is $241.09 Mil.
The historical data trend for Aratana Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aratana Therapeutics Annual Data | |||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||
Market Cap | Get a 7-Day Free Trial | 608.52 | 192.87 | 262.84 | 223.72 | 294.54 |
Aratana Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Market Cap | Get a 7-Day Free Trial | 203.01 | 199.47 | 280.21 | 294.54 | 174.05 |
For the Biotechnology subindustry, Aratana Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aratana Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Aratana Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aratana Therapeutics's Market Cap for the fiscal year that ended in Dec. 2018 is calculated as
Market Cap (A: Dec. 2018 ) | = | Share Price (A: Dec. 2018 ) | * | Shares Outstanding (EOP) (A: Dec. 2018 ) |
= | $6.13 | * | 48.0489 | |
= | $294.54 |
Aratana Therapeutics's Market Cap for the quarter that ended in Mar. 2019 is calculated as
Market Cap (Q: Mar. 2019 ) | = | Share Price (Q: Mar. 2019 ) | * | Shares Outstanding (EOP) (Q: Mar. 2019 ) |
= | $3.6 | * | 48.3473 | |
= | $174.05 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aratana Therapeutics (NAS:PETX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Aratana Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Roche Robert P Jr | director | 41 MOORES ROAD FRAZER PA 19355 |
Vort John Vander | director | C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Lowell W Robinson | director | 470 WEST END AVENUE, NEW YORK NY 10024 |
Wendy L Yarno | director | |
David L Brinkley | director | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Merilee Raines | director | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Craig A. Barbarosh | director | 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305 |
Hockaday Irvine O Jr | director | SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191 |
Craig A Tooman | director, officer: President and CEO | |
Peter Steven St | director, officer: PRESIDENT AND CEO | MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Laura Brege | director | C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608 |
Jay Lichter | director | C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211 |
From GuruFocus
By PRNewswire PRNewswire • 08-29-2018
By Marketwired Marketwired • 06-25-2019
By PRNewswire PRNewswire • 07-17-2019
By Marketwired Marketwired • 04-30-2019
By Marketwired Marketwired • 04-29-2019
By PRNewswire PRNewswire • 04-26-2019
By PRNewswire PRNewswire • 04-22-2019
By PRNewswire PRNewswire • 06-12-2019
By PRNewswire PRNewswire • 02-04-2019
By Marketwired Marketwired • 04-27-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.